No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina / NY / FL

SteadyMD Raises $25 Million Series B Capital: Lux Capital Led the Round

Editor: What To Know

  • “I have witnessed the transformation of virtual care over the last decade — as an operator and now as an investor — and I could not be more excited about the potential of telehealth to transform how care is delivered, research is conducted, and ultimately how health equity and health justice are achieved.
  • Since its Series A round in early 2020, led by Pelion Venture Partners and NEXT VENTŪRES, SteadyMD has capitalized on the technology and clinicians behind the success of its consumer business in order to help digital health companies and employers do the same for their patients and employees across all 50 states.
  • SteadyMD, a technology company and healthcare provider that delivers high-quality telehealth experiences in all 50 states, today announced a $25 million Series B capital raise to enhance the company's platform services that now power the telehealth infrastructure of digital health businesses and employers.

March 30, 2021

SteadyMD, a technology company and healthcare provider that delivers high-quality telehealth experiences in all 50 states, today announced a $25 million Series B capital raise to enhance the company’s platform services that now power the telehealth infrastructure of digital health businesses and employers.

Lux Capital led the round, with Partner Deena Shakir joining the SteadyMD Board of Directors and additional participation from Ashton Kutcher and Guy Oseary’s Sound Ventures, Acrew Capital, and other healthcare investors. The new capital comes after five years of strong growth within SteadyMD’s proven direct-to-consumer primary care offering and will support the recent expansion of its platform services, which enable telehealth providers across the care continuum to scale with a 50-state clinician workforce, legal and regulatory guidance, and supporting technology.

Founders Guy Friedman and Yarone Goren launched SteadyMD as a direct-to-consumer telehealth company in 2016, offering individuals and families unlimited, direct access to a primary care physician uniquely matched to their health and lifestyle. Since its Series A round in early 2020, led by Pelion Venture Partners and NEXT VENTŪRES, SteadyMD has capitalized on the technology and clinicians behind the success of its consumer business in order to help digital health companies and employers do the same for their patients and employees across all 50 states. SteadyMD currently works with leading employers and online-first companies delivering primary care, behavioral health, digital pharmacy, medical device, at-home lab, and other telehealth services.

“We launched SteadyMD to deliver the highest quality of care possible to patients nationwide, completely online,” said Guy Friedman, SteadyMD Co-founder & CEO. “We’ve solved the puzzle of delivering that care in all 50 states, which involves numerous product, technology, legal, clinical, and operational challenges. Today, leading healthcare organizations rely on SteadyMD for the key infrastructure to launch, scale, and grow their telehealth offerings in the massive and quickly expanding digital health market.”

“Our success on the front lines now enables us to work behind the scenes for companies with like-minded missions to design quality telehealth solutions,” said Yarone Goren, SteadyMD Co-founder & COO. “Between clinician management and staffing, predicting patient demand, patient-provider matching, legal and regulatory issues, and the technology infrastructure that goes into a best-in-class telehealth operation, we’re helping companies deliver the highest quality healthcare where patients are — online.”

In addition to Lux Capital, Sound Ventures, and Acrew Capital, several prominent healthcare executives and investment leaders participated in the Series B round, including Anne Wojcicki (co-founder of 23andMe) and Draper Associates.

“I have witnessed the transformation of virtual care over the last decade — as an operator and now as an investor — and I could not be more excited about the potential of telehealth to transform how care is delivered, research is conducted, and ultimately how health equity and health justice are achieved. The industry has only begun to scratch the surface, and the pressures of the pandemic have propelled telehealth into permanence,” said Deena Shakir, Partner at Lux Capital, who now joins SteadyMD’s board. “Guy and Yarone are exactly the type of founders we take pride in backing — mission-driven, execution-oriented, ambitious, and gritty. We are proud to be joining them on this journey to improve human health through technology.”

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy